- Home
- PENG vs VKTX Comparison
PENG vs VKTX Comparison
Compare PENG & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PENG | VKTX |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | United States | United States |
| Employees | 2900 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.3B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | PENG | VKTX |
|---|---|---|
| Price | $61.72 | $36.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $27.78 | ★ $95.86 |
| AVG Volume (30 Days) | ★ 3.0M | 2.8M |
| Earning Date | 04-01-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.55 | N/A |
| Revenue Next Year | $16.14 | N/A |
| P/E Ratio | $87.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.04 | $22.96 |
| 52 Week High | $77.40 | $43.15 |
Technical Indicators
Market Signals| Indicator | PENG | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.98 | 63.31 |
| Support Level | $19.21 | $32.66 |
| Resistance Level | $75.32 | $39.78 |
| Average True Range (ATR) | 7.44 | 2.16 |
| MACD | -0.86 | 0.72 |
| Stochastic Oscillator | 15.40 | 65.76 |
Price Performance
Historical ComparisonAbout PENG Penguin Solutions Inc. Ordinary Shares
Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.